Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene

Pain

Volumn 130, Issue 1-2, 2007, Pages 25-30

  Reyes Gibby, Cielito C ^a   Shete, Sanjay ^a   Rakvåg, Trude ^b   Bhat, Samrat V ^a   Skorpen, Frank ^b   Bruera, Eduardo ^a   Kaasa, Stein ^b,c   Klepstad, Pål ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Epidemiology; Genetic; Joint effects; Opioid; Pain

Indexed keywords

CATECHOL METHYLTRANSFERASE; MORPHINE; MU OPIATE RECEPTOR;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CATECHOL O-METHYLTRANSFERASE; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MORPHINE; MULTIVARIATE ANALYSIS; NEOPLASMS; PAIN; RECEPTORS, OPIOID, MU; REGRESSION ANALYSIS;

EID: 34249794271     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.10.023     Document Type: Article

References (50)

1. Befort K., Filliol D., Decaillot F.M., Gaveriaux-Ruff C., Hoehe M.R., and Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276 (2001) 3130-3137
2. Belfer I., Wu T., Kingman A., Krishnaraju R.K., Goldman D., and Max M.B. Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology 100 (2004) 1562-1572
3. Bendel R.B., and Afifi A.A. Comparison of stopping rules in forward regression. J Am Stat Assoc 72 (1977) 46-53
4. Bergholdt R., Taxvig C., Eising S., Nerup J., and Pociot F. CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol 77 (2005) 579-585
5. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95 (1998) 9608-9613
6. Caraceni A., Cherny N., Fainsinger R., Kaasa S., Poulain P., Radbruch L., and De Conno F. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23 (2002) 239-255
7. Chen J.F., Aloyo V.J., and Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54 (1993) 669-680
8. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., Goldman D., Xu K., Shabalina S.A., Shagin D., Max M.B., Makarov S.S., and Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14 (2005) 135-143
9. Duguay Y., Baar C., Skorpen F., and Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75 (2004) 223-233
10. Fillingim R.B., Kaplan L., Staud R., Ness T.J., Glover T.L., Campbell C.M., Mogil J.S., and Wallace M.R. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6 (2005) 159-167
11. Flores C.M., and Mogil J.S. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management 1. Pharmacogenomics 2 (2001) 177-194
12. Hoehe M.R., Kopke K., Wendel B., Rohde K., Flachmeier C., Kidd K.K., Berrettini W.H., and Church G.M. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9 (2000) 2895-2908
13. Hong S.J., Lee S.Y., Kim H.B., Kim J.H., Kim B.S., Choi S.O., Lee S.G., Shin E.S., and Hong T.J. IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. J Allergy Clin Immunol 115 (2005) 758-763
14. Infante J., Sanz C., Fernandez-Luna J.L., Llorca J., Berciano J., and Combarros O. Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology 63 (2004) 1135-1136
15. Kim H., Neubert J.K., San Miguel A., Xu K., Krishnaraju R.K., Iadarola M.J., Goldman D., and Dionne R.A. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament 3. Pain 109 (2004) 488-496
16. King T., Ossipov M.H., Vanderah T.W., Porreca F., and Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals 14 (2005) 194-205
17. Klepstad P., Dale O., Skorpen F., Borchgrevink P.C., and Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49 (2005) 902-908
18. Klepstad P., Loge J.H., Borchgrevink P.C., Mendoza T.R., Cleeland C.S., and Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 24 (2002) 517-525
19. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., and Skorpen F. The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 (2004) 1232-1239
20. Koch T., Kroslak T., Averbeck M., Mayer P., Schroder H., Raulf E., and Hollt V. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol 58 (2000) 328-334
21. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
22. LaForge K.S., Shick V., Spangler R., Proudnikov D., Yuferov V., Lysov Y., Mirzabekov A., and Kreek M.J. Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction. Am J Med Genet 96 (2000) 604-615
23. Lee Y.S., Kim H., Wu T.X., Wang X.M., and Dionne R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs 2. Clin Pharmacol Ther 79 (2006) 407-418
24. Lotsch J., and Geisslinger G. Current evidence for a genetic modulation of the response to analgesics 1. Pain 121 (2006) 1-5
25. Lotsch J., and Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J (2006)
26. Lotsch J., Skarke C., Liefhold J., and Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 43 (2004) 983-1013
27. Lotsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., and Geisslinger G. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 97 (2002) 814-819
28. Maier L.M., Chapman J., Howson J.M., Clayton D.G., Pask R., Strachan D.P., McArdle W.L., Twells R.C., and Todd J.A. No evidence of association or interaction between the IL4RA, IL4, and IL13 genes in type 1 diabetes. Am J Hum Genet 76 (2005) 517-521
29. Max M.B. Assessing pain candidate gene studies. Pain 109 (2004) 1-3
30. Mayer P., and Hollt V. Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 91 (2001) 167-177
31. Mogil J.S. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA 96 (1999) 7744-7751
32. Mogil J.S., Yu L., and Basbaum A.I. Pain genes?: natural variation and transgenic mutants. Annu Rev Neurosci 23 (2000) 777-811
33. Mor V., Laliberte L., Morris J.N., and Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53 (1984) 2002-2007
34. Nestler E.J. Molecular mechanisms of drug addiction. J Neurosci 12 (1992) 2439-2450
35. Pasternak G.W. The pharmacology of mu analgesics: from patients to genes. Neuroscientist 7 (2001) 220-231
36. Rakvag T.T., Klepstad P., Baar C., Kvam T.M., Dale O., Kaasa S., Krokan H.E., and Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116 (2005) 73-78
37. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 9 (2004) 151-160
38. SPSS, 1998. SPSS. (10.0). SPSS Inc., Chicago IL. Ref Type: Computer Program.
39. Stamer U.M., Bayerer B., and Stuber F. Genetics and variability in opioid response. Eur J Pain 9 (2005) 101-104
40. Steiner H., and Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123 (1998) 60-76
41. Thompson S.J., Koszdin K., and Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92 (2000) 1392-1399
42. Uhl G.R., Sora I., and Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96 (1999) 7752-7755
43. Wang D., Quillan J.M., Winans K., Lucas J.L., and Sadee W. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 276 (2001) 34624-34630
44. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., and Uhl G.R. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 338 (1994) 217-222
45. World Health Organisation Geneva, Cancer Pain Relief with a Guide to Opioid Availability 1996, 58 pp.
46. Xu J., Lowey J., Wiklund F., Sun J., Lindmark F., Hsu F.C., Dimitrov L., Chang B., Turner A.R., Liu W., Adami H.O., Suh E., Moore J.H., Zheng S.L., Isaacs W.B., Trent J.M., and Gronberg H. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14 (2005) 2563-2568
47. Yates J.W., Chalmer B., and McKegney F.P. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45 (1980) 2220-2224
48. Ye S., Dhillon S., Seear R., Dunleavey L., Day L.B., Bannister W., Day I.N., and Simpson I. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart 89 (2003) 1195-1199
49. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., Wang Y., and Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27 (2006) 110-117
50. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., Koeppe R.A., Stohler C.S., and Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299 (2003) 1240-1243